Literature DB >> 20976993

Tribulations of a prostate cancer trial – lessons learned from TOAD, a Cancer Council Victoria and Transtasman Radiation Oncology Group trial.

Gillian M Duchesne1, Henry H Woo, Deborah Howell, Mary Kaimakamis, Evan Kemp.   

Abstract

From 2004–2009 a total of 226 out of a target of 750 prostate cancer patients have been randomised into the Timing of Androgen Deprivation trial between immediate and delayed androgen deprivation. A screening log was kept by participating centres for the first 928 patients, which documented the reasons for non-entry into the trial; 42.7% of screened patients were ineligible and a further 33.0% were not entered for other reasons. Fewer than 10% of patients cited not wanting to be part of a clinical trial as a reason for non-entry. Strategies to improve recruitment included broadening the eligibility criteria, encouraging international collaboration, the use and support of research nurses in the private health care environment, and the use of phone follow-up. Recruitment will be completed at the number originally intended to inform the interim analysis designed to test the validity of the statistical assumptions, and a combined survival analysis with the Canadian study is planned.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20976993     DOI: 10.1111/j.1754-9485.2010.02204.x

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  1 in total

1.  Reasons for non-recruitment of eligible patients to a randomised controlled trial of secondary prevention after intracerebral haemorrhage: observational study.

Authors:  Amy E Maxwell; Mary Joan MacLeod; Anu Joyson; Sharon Johnson; Hawraman Ramadan; Ruth Bellfield; Anthony Byrne; Caroline McGhee; Anthony Rudd; Fiona Price; Evangelos Vasileiadis; Melinda Holden; Jonathan Hewitt; Michael Carpenter; Ann Needle; Stacey Valentine; Farzana Patel; Frances Harrington; Paul Mudd; Hedley Emsley; Bindu Gregary; Ingrid Kane; Keith Muir; Divya Tiwari; Peter Owusu-Agyei; Natalie Temple; Lakshmanan Sekaran; Suzanne Ragab; Timothy England; Amanda Hedstrom; Phil Jones; Sarah Jones; Mandy Doherty; Mark O McCarron; David L Cohen; Sharon Tysoe; Rustam Al-Shahi Salman
Journal:  Trials       Date:  2017-04-05       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.